ICLE 2022 | Optimizing public neoantigen-targeting immunotherapies
Chris Klebanoff
• 1 Apr 2022
Chris Klebanoff, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes the clinical translation of cell therapies targeting public neoantigens for cancer. A library of neoantigen-targeting T-cell receptors (TCRs) that have been evaluated for safety and potency will spur the development of novel immunotherapies that can target driver oncogenes. Whilst there have been no safety issues reported, barriers remain in terms of inserting the gene sequence into T-cells. Dr Klebanoff additionally discusses non-viral strategies such as CRISPR-Cas9. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
